Skip to main content
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. — Investor Relations & Filings

Ticker · GANX ISIN · US36269B1052 US Manufacturing
Open in API
Filings indexed 217 across all filing types
Latest filing 2021-01-20 Regulatory Filings
Country US United States of America
Listing US GANX

About Gain Therapeutics, Inc.

https://www.gaintherapeutics.com/

Gain Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops next-generation allosteric small molecule therapies. The company utilizes its proprietary Magellan™ drug discovery platform, which combines artificial intelligence with physics-based computational models to identify novel allosteric binding sites on disease-implicated proteins. This approach aims to modulate protein function to treat diseases that are currently undruggable. The company's lead candidate, GT-02287, is in Phase I clinical trials for the treatment of GBA-Parkinson’s disease. Gain's therapeutic pipeline targets neurodegenerative diseases, lysosomal storage disorders, and other conditions with high unmet medical needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-01-20 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a law firm to the SEC staff regarding comments on a Draft Registration Statement on Form S-1 for Gain Therapeutics, Inc. It discusses revisions to disclosures, risk factors, financial data, and business descriptions in the Registration Statement. The presence of references to Form S-1, detailed regulatory comments, and responses indicates this is part of the registration process for an initial public offering or similar securities offering. This is not a financial report, earnings release, or other types of filings but a regulatory filing related to securities registration. Therefore, the document fits best under Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication announcement but a substantive regulatory communication.
2021-01-08 English
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is a confidential draft registration statement on Form S-1 filed with the SEC for Gain Therapeutics, Inc. It includes detailed information typical of a registration statement for an initial public offering (IPO), such as offering details, underwriting, risk factors, management discussion, financial data, and legal matters. The Form S-1 is a regulatory filing used to register securities for public sale and is not a financial report like an annual or quarterly report. It is not an announcement or a brief notice but a comprehensive registration document. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers miscellaneous filings that do not fit other specific categories, including registration statements and prospectuses.
2021-01-08 English
Regulatory Filings 2020
Regulatory Filings
2020-12-14 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm submitting a draft Registration Statement on Form S-1 confidentially to the SEC for Gain Therapeutics, Inc. It references the Securities Act of 1933 and the Jumpstart Our Business Startups Act, indicating this is related to an initial public offering (IPO) registration process. The letter explicitly states this is a confidential submission of a draft Registration Statement, not the final filing or the registration statement itself. The document is short (2491 characters) and serves as a cover letter for the confidential submission. It does not contain financial data or the registration statement itself. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings and submissions that do not fit other categories.
2020-11-16 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed confidentially with the SEC by Gain Therapeutics, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The text includes detailed information about the offering, underwriting, risk factors, management, and financial data. Form S-1 is a registration statement used for securities offerings and is not a financial report like an annual or quarterly report. It is also not an announcement or a brief summary but a comprehensive filing related to capital raising. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPO registrations.
2020-11-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.